OnKure Therapeutics Files 8-K on Asset Deal & Equity Sales

Ticker: OKUR · Form: 8-K · Filed: Oct 8, 2024 · CIK: 1637715

Sentiment: neutral

Topics: acquisition, equity-sale, corporate-action

TL;DR

OnKure Therapeutics filed an 8-K on 10/4/24 detailing asset deals, equity sales, and changes in control.

AI Summary

On October 4, 2024, OnKure Therapeutics, Inc. (formerly Reneo Pharmaceuticals, Inc.) filed an 8-K detailing several significant events. These include the completion of an acquisition or disposition of assets, unregistered sales of equity securities, and material modifications to the rights of security holders. The filing also notes changes in control of the registrant and amendments to its articles of incorporation or bylaws.

Why It Matters

This 8-K filing indicates significant corporate actions, including potential changes in ownership or control and the issuance of new equity, which could impact the company's structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing involves changes in control, asset dispositions, and unregistered equity sales, which can introduce complexity and potential risks for investors.

Key Players & Entities

FAQ

What specific assets were acquired or disposed of by OnKure Therapeutics?

The filing indicates the completion of an acquisition or disposition of assets but does not specify the exact assets involved.

What was the nature of the unregistered sales of equity securities?

The 8-K filing mentions unregistered sales of equity securities but does not provide details on the type of securities or the terms of the sales.

What material modifications were made to the rights of security holders?

The filing states there were material modifications to the rights of security holders, but the specific nature of these modifications is not detailed in the provided text.

What specific event led to the change in control of OnKure Therapeutics?

The 8-K lists 'Changes in Control of Registrant' as an item, but the specific transaction or event causing the change in control is not described in the provided excerpt.

When did OnKure Therapeutics officially change its name from Reneo Pharmaceuticals, Inc.?

The filing indicates the date of the name change from Reneo Pharmaceuticals, Inc. to OnKure Therapeutics, Inc. was March 25, 2015.

Filing Stats: 4,532 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-10-08 17:26:01

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements Certain statements in this Current Report on Form 8-K and the information incorporated herein by reference may constitute "forward-looking statements" for purposes of the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the Transactions and their expected benefits; the Combined Company's performance following the Transactions; our plans relating to the clinical development of our product candidates, including the size, number and areas to be evaluated; our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and strategy; and the Combined Company's ability to obtain funding for its operations. Forward-looking statements include statements relating to our management team's expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to the Transactions. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that we have anticipated. Forward-looking statements include, but are not limited to, statements concerning the following: risks associated with t

Business

Business OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. By improving selectivity for the oncogenic and mutated form of these cancer-driver proteins, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from non-selective inhibition of the non-mutated (or wild-type) version of the protein. We believe that inhibiting target proteins with specific mutations instead of wild-type variants should enable precise patient selection that will, in turn, improve the probability of clinical success. We designed our current product candidates utilizing x-ray crystallography and computational chemistry to inhibit specified mutated versions of phosphoinositide 3 kinase alpha (" PI3K "), a key mediator in cancer growth signaling. Our lead product candidate, OKI-219, is a highly selective inhibitor of PI3K harboring the H1047R mutation (" PI3K H1047R ") that has a much smaller impact on wild-type PI3K (" PI3K WT "). We plan to initially focus on the development of OKI-219 in patients with advanced breast cancer of genetic subtypes that are (a) both hormone receptor positive (" HR+ ") and human epidermal growth factor receptor 2 negative (" HER2- "); and (b) human epidermal growth factor receptor 2 positive (" HER2+ "). We believe 4 that we can potentially expand the application of OKI-219 by conducting appropriate clinical trials in earlier lines of treatment within breast cancer, other subtypes of breast cancer, and potentially in other solid tumors. OKI-219 is currently in a first

Risk Factors

Risk Factors The risk factors related to the Combined Company's business and operations and the Transactions are set forth in the Proxy Statement/Prospectus in the section titled "Risk Factors" beginning on page 36 of the Proxy Statement/Prospectus and that information is incorporated herein by reference. Audited Financial Statements The audited financial statements as of and for the years ended December 31, 2023 and 2022 of Legacy OnKure set forth in Exhibit 99.1 hereto are incorporated herein by reference and have been prepared in accordance with U.S. generally accepted accounting principles and pursuant to the regulations of the SEC. 6 These audited financial statements should be read in conjunction with the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" included herein. Unaudited Financial Statements The unaudited financial statements as of and for the three and six months ended June 30, 2024 of Legacy OnKure set forth in Exhibit 99.2 hereto are incorporated herein by reference. These unaudited financial statements should be read in conjunction with the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" included herein. Unaudited Pro Forma Condensed Combined Financial Information The unaudited pro forma condensed combined financial information of the Combined Company for the three and six months ended June 30, 2024 and year ended December 31, 2023 is set forth in Exhibit 99.3 hereto and is incorporated herein by reference.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations Reference is made to the disclosure in the sections titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in (i) Reneo's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 28, 2024 (as amended by Amendment No. 1 on Form 10-K/A, filed with the SEC on April 26, 2024), beginning on page 88 of the Annual Report on Form 10-K, which is incorporated herein by reference, and (ii) Reneo's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, filed with the SEC on August 13, 2024, beginning on page 18 of the Quarterly Report on Form 10-Q, which is incorporated herein by reference. Management's discussion and analysis of the financial condition and results of operation of Legacy OnKure as of and for the year ended December 31, 2023 and the three and six months ended June 30, 2024 is set forth below. The following discussion and analysis provides information that the Combined Company's management believes is relevant to an assessment and understanding of the Combined Company's results of operations and financial condition. The discussion should be read together with the audited financial statements and related notes and unaudited pro forma condensed financial information that are included elsewhere in this Current Report on Form 8-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. The Combined Company's actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the Proxy Statement/Prospectus in the section titled "Risk Factors" beginning on page 36 of the Proxy Statement/Prospectus or in other parts of this Current Report on Form 8-K. Unless the context otherwise requires, references in this "Managem

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing